Ginkgo Bioworks reported a significant reduction in cash burn and reaffirmed its 2025 revenue guidance, despite a challenging environment in the biotechnology sector.

• Quarterly cash burn decreased by 75% year-over-year to $28 million, significantly improving the company's cash position with $462 million in cash and no bank debt.
• Cell Engineering revenue fell 61% year-over-year to $29 million due to a previous noncash revenue spike; adjusted revenue was down only 11% compared to the prior year.
• Biosecurity revenue reached $9 million with a gross margin of 19%, and segment operating loss improved by 21% from a year prior.
• The company remains focused on expansion in AI and automation, with plans to deliver autonomous labs at customer sites.
• Ginkgo reaffirmed its full-year 2025 revenue guidance between $167 million and $187 million, with expectations for Cell Engineering revenue to range from $117 million to $137 million.